FDA approves two biosimilars to blockbuster eye drug Eylea

The U.S. Food and Drug Administration on Monday approved two close copies of Regeneron Pharmaceuticals' (REGN.O) blockbuster eye drug, Eylea, potentially hurting the company's efforts to market a higher dose version of the treatment.